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Impairment of homologous recombination (HR), a vital process employed during repair of DNA dou-
ble strand breaks and stalled DNA replication, provides a valuable opportunity for the cell to become
transformed. Once transformed, the impairment turns to be a target for therapy as exempliﬁed by
the synthetic lethal strategy such as poly (ADP-ribose) polymerase (PARP) inhibitor for BRCA1/2-
defective breast and ovarian cancer. Hence, improving mechanistic understanding of HR has
emerged as an urgent issue to address due to the high clinical demand. Ubiquitin modiﬁcation plays
a central role in HR and more than a few E3 ubiquitin ligases have been implicated in the process.
However, the signiﬁcance of the activity of one such key E3 ligase, BRCA1, has not yet been clariﬁed
and remains as a major obstacle in the ﬁeld. Here, we review recent advances in our understanding
of BRCA1 function in HR and discuss possible roles of the activity.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Ubiquitin modiﬁcation plays crucial roles in most of, if not all,
the cellular functions including proteolysis, trafﬁcking, signal
transduction, and DNA repair. The involvement of ubiquitin in
DNA repair processes has been clariﬁed by a fact that one of
DNA repair genes, RAD6, was characterized as an E2 ubiquitin-
conjugating enzyme [1]. Afterward Lys-63 (K63)-linked ubiquitin
chains have been shown to be essential for DNA repair in yeast
[2]. Two decades later it is now generally accepted that ubiquitina-
tion plays central roles in multiple DNA repair cascades and vari-
ous E3 ubiquitin ligases for the ubiquitin chains have been
identiﬁed with their distinctive functions. In mammalian cells
homologous recombination (HR) repair is organized by at least se-
ven E3 or E3 complexes, BRCA1/BARD1, RNF8, RNF20/40, RNF168,
RAD18, HERC2, and polycomb-repressive complex 1 [3–15]. The
signiﬁcances of the activities have been shown for some of the
E3 ligases. In contrast, the signiﬁcance of the E3 ligase activity of
BRCA1 (breast and ovarian cancer susceptibility protein 1) is still
obscure, despite it was the ﬁrst mammalian E3 enzyme shown
to function at sites of DNA damages [16,17]. BRCA1 forms a RING
heterodimer with BARD1 (BRCA1-associated RING domain 1), an
interaction necessary for BRCA1 protein stability, nuclear localiza-
tion, and the E3 ligase activity [16,18–20]. Both BRCA1 and BARD1al Societies. Published by Elsevier
ional Oncology, St. Marianna
6-8511, Japan.are absolutely required for HR and other critical cellular events in
response to DNA damage, and loss of either protein results in sus-
ceptibility to breast cancer. However, how the E3 ligase activity
contributes to these events, or even whether the activity is indeed
inevitable, would be controversial. In this review, we have summa-
rized current knowledge concerning BRCA1 functions in HR, and
attempted to interpret the role of BRCA1’s E3 ligase activity in
the process.
2. BRCA1 functions in HR
The essential role of BRCA1 in response to DNA damage has ﬁrst
been shown by mouse embryonic stem (ES) cells or ﬁbroblasts
(MEFs) carrying a targeted deletion of exon 11 of the BRCA1 gene.
Exon 11 is the largest exon required for the interaction with
RAD51, a critical effecter for HR [21], and the cells lacking the exon
were defective for G2/M checkpoint [22] and DNA double-strand
breaks (DSBs) repair by HR [23]. The BRCA1 gene encodes a protein
of 1863 amino acids [24]. The protein consists of a RING ﬁnger
domain in its N-terminal region and tandem BRCT domains in its
C-terminal region in addition to a region encoded by the exon11
in the middle. The N-terminal RING ﬁnger domain interacts with
BARD1, which also contains an N-terminal RING domain and
C-terminal tandem BRCT domains [25,26]. The BRCT repeat of
BRCA1 is a phospho-protein binding module and interacts with
phosphorylated Abraxas, BACH1 (also called FANCJ or BRIP1) and
CtIP in mutually exclusive manner, and thereby contributes to
the formation of three distinct complexes, called BRCA1-A, B, andB.V. Open access under CC BY-NC-ND license.
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an interaction bridged by PALB2 [32,33]. Thus BRCA1 forms several
key protein complexes that distinctively and cooperatively func-
tion in response to DNA damage. The BRCA1–BARD1 RING hetero-
dimer exists in all the BRCA1 complexes as a core component. Key
functions of each complex in response to DNA damage have grad-
ually been revealed.
2.1. DSB end-resection by BRCA1-CtIP
The site of DNA damage is recognized by damage sensor com-
plex comprising Mre11, RAD50 and NBS1 (MRN) in the initial steps
of HR [34]. Mre11 has endonuclease and exonuclease activities
[35,36] (Fig. 1). MRN promotes the recruitment of ATM to DSBs
that is essential for phosphorylation of histone H2AX and subse-
quent phosphorylation of MDC1 that allows RNF8 cascade
[34,37,38]. In addition MRN recruits BRCA1-CTIP through direct
binding to phosphorylated CtIP and forms BRCA1-C complex [39].
BRCA1-CtIP, in conjunction with the MRN complex, mediates
extensive DSB end resection that generates single strand DNA
(ssDNA) overhangs to support subsequent HR-mediated repair of
DSB [40,41].Fig. 1. Homologous recombination repair pathway for DSBs carried out by ubiquitin m
(BRCA1-A) complexes. Various E3 ubiquitin ligases, DUB enzymes, and E3 SUMO ligasesOn the other hand CtIP is capable of generating limited DSB end
resection without BRCA1 to promote altered non-homologous end
joining (alt-NHEJ), an error-prone repair in G1 phase of cell cycle
mediated by the annealing of microhomology regions [42]. The
switch from alt-NHEJ to HR is mediate by phosphorylation of Ser
327 of CtIP in S-phase that promotes BRCA1 interaction (Fig. 1).
The DSB end resection promoted by CtIP is inhibited by 53BP1,
and BRCA1 overwhelm 53BP1 to execute the resection [43]. This
inhibition is important for protection of alt-NHEJ in G1-phase
when CtIP does not interact with BRCA1, to support Ku-mediated
NHEJ [44]. In addition 53BP1 blocks HR and sustain the growth ar-
rest induced by BRCA1 depletion [43,45]. Interestingly loss of
53BP1 partially rescues the BRCA1 deﬁciency and is associated
with breast cancer development [45]. Together, one major function
of BRCA1 in the BRCA1-C complex is suppression of 53BP1 and pro-
longation of the CtIP activity for DSB end resection to generate
ssDNA length long enough for HR.
2.2. Recruitment of BRCA1 by K63-linked ubiquitin conjugates
K63-linked polyubiquitin chains assembled on PCNA plays
critical roles in postreplication DNA repair. In addition theirodiﬁcation focused on the functions of BRCA1-CtIP (BRCA1-C) and BRCA1-RAP80
are involved in the process. Details are described throughout the text.
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of RAP80 that recruits BRCA1 to the sites of DSBs [29,46,47] (Fig. 1).
RAP80 constitutes BRCA1-A complex (RAP80-Abraxas-BRCA1) and
directs the complex to the K63-linked ubiquitin chains through its
tandem UIM (ubiquitin-interacting motif) domains (Fig. 1). Subse-
quently RNF8 was discovered to be a RING type E3 ligase that is re-
cruited to DSBs in a manner dependent on ATM phosphorylation of
MDC1 and generates K63-linked ubiquitin chains required for the
downstream HR process [4–7]. The ubiquitin products mediated
by RNF8 were not sufﬁcient for exertion of HR, and RNF168, an-
other RING type E3 ligase, was later found to enhance the K63-
linked polyubiquitination [8,9]. RNF168 contains MIU (motif inter-
acting with ubiquitin) domain and directly interacts with K63-
linked ubiquitin conjugates initially generated by RNF8.
Components in the BRCA1-A complex including Abraxas, BRE/
BRCC45, BRCC36, and NBA1/MERIT40 were also shown to directly
interact with ubiquitin conjugates in vitro through MPN, Uev,
MPN+, and VWA domains, respectively [48]. NBA1/MERIT40 inte-
grates the complex through maintaining the stability of BRE/
BRCC45 and is required for BRCC36-mediated deubiquitinating en-
zyme (DUB) activity in the complex [49,50]. In addition to the
above ubiquitin-interacting proteins, nucleophosmin (NPM1, also
called B23), a candidate substrate for BRCA1 E3 activity [51], is re-
cruited to DSBs in a manner dependent on the RNF8/RNF168-med-
iated ubiquitin conjugates [52] (Fig. 1). Signiﬁcantly NPM1
interacts with K63-linked ubiquitin polymer in vitro with high
afﬁnity. The afﬁnity relies on phosphorylation of Thr199, an acidic
tract, and an adjacent UIM-like domain within NPM1 [52]. All the
components recruited by the ubiquitin conjugates are likely essen-
tial for efﬁcient HR. Speciﬁc tasks for individual proteins in the pro-
cess have progressively been elucidated.
Production of the K63-linked polyubiquitin chains by RNF8 and
RNF168 are regulated by complex mechanisms through accessibil-
ity of their vital E2 enzyme, UBC13. HERC2, a HECT type E3 ligase
and a DUB OTUB1 have been involved in the mechanisms (Fig. 1).
HERC2, an enormously large 4834 amino acid protein comprising
three RCC1-like domains and a C-terminal HECT domain, interacts
with the FHA domain of RNF8 in a phosphorylation-dependent
manner and facilitates assembly of the RNF8-UBC13 complex
[11]. It also maintains the level of RNF168. In contrast to HERC2,
OTUB1 binds to and inhibits UBC13 and thereby suppresses
RNF168-dependent polyubiquitination [53]. Interestingly neither
HERC2 nor OTUB1 requires its enzymatic activity, i.e., E3 ligase
activity or DUB activity, respectively, to regulate RNF8 and
RNF168. This may suggest that they further contribute to DSB re-
pair process on different aspects by regulating ubiquitination sta-
tus with the speciﬁc activities. One such function for HERC2
could be its action toward BRCA1 as described later.
Although precise mechanisms for the ubiquitin-dependent
recruitment of RAP80-Abraxas-BRCA1 (BRCA1-A) complex has
been elucidated as described, the role of BRCA1 in this pathway
is not clear. In this regards, an unexpected function of this complex,
where it compete with the other complexes for BRCA1, was re-
cently discovered (Fig. 1). Whereas RAP80 is required for ionizing
radiation-induced foci (IRIF) formation of BRCA1 at late stage after
IR, it is dispensable for the IRIF formation at early stage, until 1 h
after IR [54]. The early BRCA1 recruitment to DSBs is likely medi-
ated by CtIP and BACH1. Interestingly RAP80 depletion led to sig-
niﬁcantly higher rate of DSB end processing as detected by IRIF
formation of ssDNA binding protein RPA or that of BrdU in non-
denaturing condition [54,55]. It is accompanied by enrichment of
CtIP, BACH1 and RAD51 at DSBs, and leads to an increased fre-
quency of HR in reporter cells [54,55]. Importantly the excess HR
activity renders cells to develop gross chromosomal rearrange-
ments [54]. This suggests that appropriate tuning of BRCA1 activity
for DSB end resection and HR is critical for genome integritymaintenance. BRCA1-A complex perform this task by suppressing
BRCA1-C complex.
2.3. Recruitment of RAD51 recombinase by BRCA1
DNA strand invasion into homologous sequences of the sister
chromatid, the main event for the reaction of HR repair is carried
out by recombinase RAD51 [56] (Fig. 1). The ssDNA binding protein
RPA ﬁrst interacts with and occupies the 30 single strand overhangs
generated by the BRCA1-CtIP. RAD51 next replaces RPA and consti-
tutes ssDNA-RAD51 ﬁlament under guidance of BRCA2, which is
capable of holding several RAD51 molecules through 8 BRC repeats
[57,58]. The RAD51 ﬁlament then searches for the homologous re-
gion. BRCA1 is essential for the retention of BRCA2 and RAD51 at
the DSB site [59]. This is one of the principal roles of BRCA1 in
the HR process in addition to the DSB end resection.
The recruitment of BRCA2 by BRCA1 is mediated by PALB2,
which acts as a linker between the two proteins [32,33] (Fig. 1).
However, how the BRCA1–PALB2–BRCA2 complex is recruited to
the DSB sites is obscure. Because PALB2 binds to BRCA1 outside
of its BRCT domains, it is possible that one of three BRCA1 com-
plexes, i.e., A, B and C, may contain the BRCA2-RAD51. However,
depletion of neither RAP80 nor BACH1 abolishes the IR-induced
RAD51 foci formation [54,60]. In addition neither BACH1 nor
RAD50 coimmunoprecipitated BRCA2, and reciprocally BRCA2 did
not coimmunoprecipitate either protein while it did RAD51 [59].
These results suggest that the retention of BRCA1–PALB2–BRCA2
at the site of DNA damage is independent of other three BRCA1
complexes. Alternatively PALB2–BRCA2 may replace other
BRCA1-interacting proteins after BRCA1 is recruited to the DSB
sites. Mechanism organizing the order of accumulation of the four
BRCA1 complexes to recruit BRCA2-RAD51 is a critical issue to be
elucidated.3. E3 ligase activity of BRCA1 in HR
One remarkable feature for BRCA1 is its E3 ligase activity that is
acquired by constitution of a RING heterodimer with BARD1, a core
complex residing in most of BRCA1 complexes [16,59]. Because all
four BRCA1 complexes critical for HR contain this core complex,
the activity is likely important for the process. However, there
are some hardships to obtain direct evidence for the signiﬁcance
of the activity. Nonetheless several indirect evidences suggest its
requirement.
3.1. Is BRCA1 E3 activity required for HR?
The potential importance of the E3 ligase activity of BRCA1 in
cellular pathways was supported by the fact that many missense
mutations within RING ﬁnger domain of BRCA1, which causes
familial breast cancer, abolished the E3 activity [16,18,61]. These
mutants are unable to restore gamma-radiation sensitivity, G2/M
checkpoint activity and HR in BRCA1 defective cells [61,62]. How-
ever, most of the mutations that eliminate the activity also abolish
the interaction with BARD1. Because the in vivo stabilities and nu-
clear localization of BRCA1 and BARD1 are interdependent
[16,19,20,63], the phenotype observed in these mutations are
attributed to the total BRCA1 deﬁciency. Indeed, mouse models
with mammary epithelial cells targeted ablation of BRCA1, BARD1,
or both developed breast carcinomas that are indistinguishable
among the genotypes with respect to their frequency, latency, ba-
sal-like histopathology, and cytogenetic features [64].
In order to analyse the genuine signiﬁcance of the E3 activity,
mutations that only abolish the activity but does not affect other
functions including the protein stability or BARD1 binding is ideal.
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rupt the interaction of E2 enzymes without perturbing the BRCA1–
BARD1 complex revealed that the E3 ligase activity strongly corre-
lates with breast cancer susceptibility [65]. However, to our sur-
prise, genetically engineered mouse ES cells expressing BRCA1
with substitution of alanine for isoleucine at position 26 (I26A), a
popular mutation to disrupt the E2 binding without perturbing
BARD1 binding [18], did not exhibit HR failure [66]. The ES cells
with BRCA1 I26A were resistant to genotoxic stress, were capable
of accumulating RAD51 at DSBs, and mediated HR repair at the
same level as cells with wild type BRCA1. Nonetheless a few ques-
tions have been evoked before conclude that E3 activity of BRCA1
is dispensable for HR.
First, DNA repair capacity of ES or stem cells is different from
that of differentiated cells [67,68]. To maintain the genetic stability
in daughter cells, ES cells must have robust mechanisms to protect
their DNA from damages. Basically ES cells are proﬁcient in HR as
evidenced by their use in gene targeting experiments. They grow
quickly with very short G1 and G2 phases and express much higher
level of RAD51 than MEFs do [68]. It has been reported that over-
expression of RAD51 in BRCA1 deﬁcient DT40 cells rescues defects
in proliferation, DNA damage survival, and HR [69]. Together, the
demand for BRCA1 in the ES cells could be less than that in differ-
entiated cells. Indeed the expression level of BRCA1 I26A in the ES
cells was considerably low while the cells were intact for HR [66].
Second possibility is that the E3 ligase activity of BRCA1 could
be required for HR process in response to some speciﬁc type of
DNA damage. The DNA damage utilized in the previous report
was that introduced by either IR, mitomycin C (MMC) or the
restriction enzyme I-SceI [66]. These agents induce either DNA
cross-linking or DSB. However, other types of DNA damage that
employs HR in the process, such as that induced by PARP inhibitor
may requires BRCA1 E3 activity.
Third, the ES cells expressing inactive BRCA1 E3 ligase showed
elevated level of damage-induced, but not spontaneous, chromo-
somal abnormalities. The mutant cells showedMMC-induced chro-
mosomal aberration at higher level than wild type BRCA1 [66]. This
suggests that the DNA repair system in the cells is not totally intact
although the luck of function could not be detected by other proce-
dures. It will be important to determine whether the observed ge-
netic instability is sufﬁcient to cause breast cancer in the mice.
Lastly the mutations in RING ﬁnger of BRCA1 that affect the E3
ligase activity were also investigated in HeLa cells for HR compe-
tence. Interestingly some mutations that disrupt the interaction
of E2 enzymes without perturbing the BARD1 binding, including
T18M, T37R and H41R [65] (Nishikawa and Ohta, unpublished
data), remarkably inhibited HR [62]. Collectively the signiﬁcance
of E3 ligase activity of BRCA1 in HR needs to be further investigated
in different settings.
3.2. Ubiquitin conjugates at DSBs mediated by BRCA1
Ubiquitin has seven lysine residues (K6, K11, K27, K29, K33, K48
and K63) and is capable of forming seven distinct types of chains
[70]. In addition linkage through C-terminal glycine of a ubiquitin
and N-terminal methionine of another ubiquitin creates linear
ubiquitin chains [71]. While K11 and K48 chains signal for proteol-
ysis by the proteasome, K63-linked and linear chains as well as
mono-ubiquitination regulates the assembly of protein complex.
However, the ubiquitin chains catalyzed by BRCA1 were shown
to be K6-linked in vitro using UbcH5 as E2 enzyme, or in vivo using
cells overexpressing BRCA1, BARD1 and mutant ubiquitins
[51,72,73]. The K6-linked ubiquitin chains are not recognized by
proteasome and likely signals other than proteolysis [72]. Ad-
versely K6-linked chains could stabilize substrates because BRCA1
mutants that lack E3 ligase activity and therefore fails to be auto-ubiquitinated are relatively unstable [66]. The most conceivable
function of K6-linked chains at present is to assemble protein com-
plexes that are critical for HR process, similar to K63-linked chains.
Earlier reports showed that ubiquitin structure accumulated at
DSBs after IR was BRCA1 dependent and was inhibited by BRCA1
depletion by siRNA or by the expression of ubiquitin with K6R
mutation [17,74]. The ubiquitin at DSBs were detected by FK2 anti-
body that exclusively recognizes conjugated ubiquitin. Later stud-
ies demonstrated that the FK2-IRIF were detected even in BRCA1
depleted cells [6]. The primary E3s that is required for the FK2-IRIF
is now known to be RNF8 and RNF168 as described above. How-
ever, because knockdown of BRCA1 reduced the FK2-IRIF [6], it is
likely that BRCA1-mediated ubiquitination occurs at the sites of
DNA damage in addition to RNF8/168-mediated ubiquitin conju-
gates. The K6-, in addition to K63-linked chains, are capable of
interacting with RAP80 and therefore may contributes to recruit
BRCA1-A complex [47]. Together one may consider that RAP80
(BRCA1-A) complex acts as positive feedback loop for accumula-
tion of the ubiquitin conjugates. However, interestingly, inhibition
of RAP80, in addition to BRCC36, a DUB subunit in BRCA1-A com-
plex, remarkably enhances the accumulation of conjugated ubiqui-
tin at DSBs [75]. This suggests that the DUB activity mediated by
BRCC36 carries greater weight than the ubiquitination mediated
by BRCA1 in the RAP80 complex in response to DNA damage,
and could be consistent with the role of BRCA1-A complex as a
negative regulator for BRCA1-CtIP-mediated end resection as de-
scribed above (Fig. 1). If this is the case, BRCA1-CtIP and/or
BRCA1–BACH1 complexes, instead of BRCA1-RAP80 complex
would be responsible for the BRCA1-induced enhanced FK2-IRIF
in normal setting.
BRCA1 is capable of creating K63- or K48-linked chains in vitro
in combination with distinct E2s, UBC13/MMS2 or UBE2K, respec-
tively, in addition to K6-linked ubiquitin chains [76]. Mono-ubiqui-
tination by UBE2W on substrates is required as a ﬁrst step in the
reaction that is subsequently recognized by the second E2s,
UBC13/MMS2 or Ube2K, whereas UBCH5-mediated K6-linked
ubiquitin polymers do not require the initial E2. UBCH5c is re-
cruited to the sites of DNA damage after IR and interacts with
BRCA1 in UBC13 dependent manner [74,77]. Whether UBE2w
and UBE2K also acts in response to DNA damage remains to be
determined.
3.3. Candidate substrates in HR
To uncover the signiﬁcance of the E3 ligase activity of BRCA1 in
HR, the identiﬁcation of its bona ﬁde substrate(s) in the process is
probably the most important step. However, several hardships
have been keeping researchers including us away from the direct
evidences to prove it since the activity was discovered 10 years
ago [16]. Such evidences may include: (a) BRCA1 dependent ubiq-
uitination of endogenous substrate(s) at DSBs under physiological
condition. (b) Direct in vitro ubiquitination of substrate(s) by
BRCA1–BARD1 in pure recombinant system. (c) Demonstration of
physiological signiﬁcance of the substrate ubiquitination in
BRCA1-related functions.
Difﬁculties to demonstrate each evidence may include: (a) Out-
come of the assay heavily rely on the efﬁcacy of the antibody used
for immunoprecipitation which may require dinature condition;
preparation of soluble chromatin fraction is required before
immunoprecipitation; prevention of contaminated DUB activity is
inevitable; cells with or without BRCA1 (ideally BRCA1 E3 activity),
possessing otherwise identical genetic backgrounds are essential.
(b) Puriﬁcation of full-length dimer, or shorter fragments that
contain the substrate recognition site, are required; Bona ﬁde E2
is not totally clear; If UbcH5 is used, low-grade ubiquitination
could be observed for many different non-speciﬁc substrates
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is determination of the phenotype of a ubiquitin-insensitive mu-
tant of the substrate. However, UbcH5c self-assembles E2-ubiqui-
tin oligomer through non-covalent interaction with ubiquitin in
addition to a covalent thiolester with the C-terminus of ubiquitin
that allows multiple mono- or poly-ubiquitination at many lysine
residues on a single protein in vitro [78,79]. Therefore identiﬁcation
of the speciﬁc ubiquitin-binding site(s) is almost impossible;
mutation that inhibits E3-substrate interaction could be valuable.
So far there are no substrates that perfectly satisfy the criteria.
Nonetheless, two potential substrates, CtIP and NPM1 that are in-
volved in HR have been demonstrated. Phosphorylated CtIP inter-
acts with BRCT domains of BRCA1 and plays critical role in DSB
end resection in HR as described above.
CtIP can be ubiquitinated by BRCA1–BARD1 in vitro and in vivo
[80]. The ubiquitinated CtIP in the chromatin extraction was
clearly observed after IR in BRCA1-deﬁcient HCC1937 cells only
when enzymatically active BRCA1 was exogenously expressed.
The ubiquitination depends on Ser 327 residue of CtIP, the phos-
phorylation site essential for interaction with BRCA1 BRCT domain.
Importantly only wild-type BRCA1, but not the I26A E3 ligase mu-
tant of BRCA1, restored CtIP IRIF formation. The results suggests
that BRCA1-mediated ubiquitination of CtIP is required for its
retention on chromatin (Fig. 1). Ubiquitination of BACH1 and
RAP80, the other two phosphorylation-dependent binding partners
for BRCA1, have not yet been reported.
Another candidate substrate, NPM1, was initially identiﬁed as a
substrate for BRCA1 by two different screen methods using mass-
spectrometry [51]. One is a screen of BRCA1 I26A immunocomplex
from a cell lysate. The other is a screen of FLAG-ubiquitin immuno-
complex precipitated from a supernatant of ubiquitin ligation reac-
tion containing FLAG-ubiquitin and BRCA1 immunoprecipitation.
Recently it was shown that NPM1 phosphorylated at Thr199 is re-
cruited to DSBs by RNF8/RNF168-mediated ubiquitin conjugates
[52] (Fig. 1). IR-induced direct or close interaction between BARD1
and NPM1 at DSBs was demonstrated as Venus ﬂuorescent foci,
which is comprised of BARD1 and NPM1 fused to truncated N-
and C-terminus of Venus protein, respectively. Importantly
replacement of endogenous NPM1 with its non-phosphorylable
T199A mutant prolongs the persistence of IR-induced RAD51 foci
accompanied by unrepaired DNA damage.
NPM1 is an abundant nucleolar phosphoprotein that partici-
pates in multiple cellular processes including ribosome biogenesis
and transport, possesses anti-apoptotic activity, regulates centro-
some duplication, and plays crucial roles in ARF-MDM2-p53 path-
ways [81]. Structural and biochemical analyses demonstrated that
NPM1 is a decameric histone chaperone that interacts with core
histones [82–84]. It is clinically important in haematopoietic tu-
mours because chromosomal translocations resulting in chimeric
NPM1-kinase fusion proteins cause anaplastic lymphomas
[85,86], and mutations generating a C-terminal extension are fre-
quently found in acute myeloid leukemia [87]. NPM1 is efﬁcient
substrate for BRCA1 either in vitro [52,88] or in vivo using exoge-
nously expressed proteins [51]. However, BRCA1 dependent ubiq-
uitination of endogenous NPM1 in response to DNA damage
remains to be demonstrated.
Other previously reported candidate substrates for BRCA1 in-
clude histones, FANCD2, the largest subunit of RNA polymerase II
(RPB1), c-tubulin, estrogen receptor a, the common subunit of
RNA polymerases RPB8, progesterone receptor-A, and the general
transcription factor TFIIE [89–96]. Of these closely relevant to HR
were histones and FANCD2. Mono-ubiquitination of FANCD2 is a
key step in DNA cross-link repair mediated by Fanconi anemia
complex. However, FANCL has been later discovered as a bona ﬁde
E3 for FANCD2 and BRCA1 was ultimately excluded from the can-
didate E3 responsible for the reaction [97–99].Histone H2A and H2AX were used as model substrates for
BRCA1 E3 ligase activity in vitro in earlier reports [61,100]. They
were mono-ubiquitinated in the reactions with E2 Ubc4 or
UbcH5c. Later histones H2B, H3, and H4, in addition to H2A and
H2AX were shown to be mono-ubiquitinated in vitro with mixture
containing BRCA1–BARD1 and UbcH5a, whereas histone H1 was
not [101]. This may suggest some speciﬁcity, however, UbcH5 type
E2s are promiscuous in vitro and low level of ubiquitination includ-
ing mono-ubiquitination can be observed on many different sub-
strates as described above [78]. In vivo evidence for BRCA1-
mediated ubiquitination of these histones has not yet been demon-
strated. Instead c-H2AX can be mono-ubiquitinated after IR in
BRCA1/ DT40 cells although the level of ubiquitination is re-
duced [77]. In addition bona ﬁde E3s for mono- or polyubiquitina-
tion of H2A, H2AX and H2B in HR process have been identiﬁed.
K63-linked polyubiquitination of H2A and H2AX essential for
recruitment of BRCA1-RAP80 is primarily mediated by the collabo-
ration of RNF8 and RNF168 [4–7,9102]. In addition mono-ubiquiti-
nation of H2A and H2B is dramatically reduced in RNF8-deﬁcient
MEFs, which abolishes BRCA1 accumulation at DSBs [103]. The
ubiquitination of H2B in response to DNA damage may not be di-
rect effect of RNF8, because RNF20 and RNF40 were found to be
the E3 responsible for the reaction [12,13]. The RNF20/40-medi-
ated H2B ubiquitination at lysine120 renders DNA relaxation
allowing subsequent DSB end resection and recruitment of BRCA1
and RAD51. Another E3 that has recently been demonstrated as an
E3 responsible for c-H2AX ubiquitination is BMI1, a subunit of
polycomb repressive complex 1 [14,15]. BMI1 is recruited to DSBs
and is requited for DNA damage-induced ubiquitination of H2A at
lysine 119 as well as for recruitment of RAP80 and BRCA1.
Thus major role of ubiquitination of H2A and H2B is likely to
create initial ubiquitin conjugates scaffold and to generate chroma-
tin relaxation that are required for recruitment of downstream re-
pair proteins including BRCA1. If BRCA1 also ubiquitinates the
same substrates after the initial ubiquitination, the speciﬁc role
of the activity would be obscure. It is not conceivable that BRCA1
ubiquitinates the histones to extend the relaxed chromatin in the
frank regions of DSBs because the role of BRCA1–RAP80 complex
that is recruited to DSBs at late phase, is to suppress, rather than
create, the end resection [54,55]. Nonetheless, it is possible that
additional relaxation of chromatin could be required for other pro-
cesses including the strand invasion or polymerization of DNA.4. Regulation of BRCA1 E3 ligase in HR
The activities of many kinases are up or downregulated in re-
sponse to DNA damage by covalent modiﬁcation such as phosphor-
ylation at a critical residue that renders conformational alteration
as exempliﬁed by ATM and Chk2 [104,105]. On the other hand,
such a regulation of E3 ligases in HR process has not been common.
However, some important modiﬁcations or protein interactions
that regulate the E3 ligase activity of BRCA1 has been
demonstrated.
4.1. Sumoylation
The importance of SUMO modiﬁcation in HR has been revealed
by the requirement of PIAS1 and PIAS4, the E3 ligases for SUMO, in
the process [106,107] (Fig. 1). PIAS1 and PIAS4 are recruited to
DSBs in a SAP domain dependent manner, and generate accumula-
tion of SUMO1, 2, and 3 at the sites. Depletion of PIAS1 or PIAS4 re-
duced the proportion of cells displaying BRCA1 accumulation and
decreased BRCA1 staining intensity at DSBs. PIAS1 or PIAS4 deple-
tion also dramatically impaired ubiquitin-conjugate accumulation
detected by FK2 antibody whereas RNF8 accumulation appeared
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paired only in PIAS4 depleted cells but not in PIAS1 depleted cells.
Because 53BP1 recruitment does not require BRCA1- or PIAS1-
mediated intended ubiquitin conjugates but requires PIAS4, it
may rely on mono-ubiquitination of histones mediated by
RNF168. In this regards, the amount of focal ubiquitination may
determine the pathway to repair DSBs, NHEJ or HR. Importantly
SUMO modiﬁcation of BRCA1 signiﬁcantly increases the E3 ligase
activity of BRCA1–BARD1 heterodimer in vitro, and mutations at
the sumoylation sites of BRCA1, K199R and E121R, dramatically re-
duced the conjugated ubiquitin foci formation [107].
4.2. Phosphorylation
BRCA1 is phosphorylated by several kinases involved in either
cell cycle regulation or DNA damage response, including CDK2,
ATM, ATR, Chk2, and CK2 [108–112]. BARD1 is also phosphorylated
by CDK2, or at ATM/ATR consensus sites in response to DNA dam-
age [113,114]. While these kinases have been shown to regulate
the distinct functions of BRCA1, the direct regulation of BRCA1
E3 ligase activity by the kinases through phosphorylation of either
BRCA1 or BARD1 has not demonstrated. Overexpression of CDK2
causes BARD1 phosphorylation at multiple sites in its N-terminal
regions and inhibits the E3 ligase activity of BRCA1–BARD1
in vivo [113]. However, unphosphorylatabole mutant of BARD1
can still be inhibited by CDK2.
4.3. Deubiquitination
In general E3 ligases interacts with DUBs and coordinately reg-
ulates ubiquitination levels in cellular pathways. The DUBs shown
to act in HR are BRCC36 and OTUB1. Whereas the role of DUB activ-
ity of OTUB1 is not apparent at present as described above, the
DUB activity of BRCC36 likely plays signiﬁcant role in BRCA1-A
complex, because inhibition of BRCC36 results in enhanced conju-
gated ubiquitin accumulation at DSBs [75]. Whether the activity is
toward ubiquitin conjugate mediated by BRCA1 or that mediated
by RNF8/RNF168 is not clear. However, because inhibition of
RAP80 that prohibits recruitment of both BRCC36 and BRCA1 also
results in the enhanced conjugated ubiquitin accumulation [75],
and because BRCC36 is K63-speciﬁc DUB [115], it is likely that
BRCC36 regulates RNF8/RNF168-mediated ubiquitination. BRCC36
may also have a role to deubiquitinate K63-linked chains mediated
by BRCA1-UBC13 in the BRCA1-A complex to lead K6-linked ubiq-
uitin chains predominant.
Another DUB that possibly cooperates with BRCA1 in HR is BAP1
(BRCA1 associated protein 1), a nuclear-residing ubiquitin C-termi-
nal hydrolase (UCH). BAP1 had been originally identiﬁed as a pro-
tein that interacted with the RING ﬁnger domain of BRCA1, before
the E3 ligase activity of BRCA1 has been discovered [116]. BAP1 also
directly interacts with BARD1. Interestingly, BAP1 inhibits the E3 li-
gase activity by interfering the RING heterodimer formation by
BRCA1 and BARD1, in addition to that it deubiquitinates the ubiqui-
tin conjugates catalyzed by BRCA1–BARD1 [88]. There is no clear
evidence for BAP1 involvement in HR. However, BAP1 has been
identiﬁed by proteomic analysis as a protein phosphorylated in re-
sponse to DNA damage on consensus sites recognized by ATM and
ATR [117]. Recently mutations of BAP1, including that perturb
BARD1 interaction, were identiﬁed to be signiﬁcantly correlate to
metastatic uveal melanomas of the eye [118].
4.4. Inhibiting E2
E2 enzymes that interact with E3s do not always activate the
ubiquitin ligation reactions. Indeed UbcH7, which interacts with
RING ﬁnger domain of BRCA1 with high afﬁnity, do not exhibitany activity with BRCA1–BARD1 in vitro [18] (Nishikawa and Ohta,
unpublished data). Interestingly, UBXN1, an E2 that inhibits
BRCA1–BARD1 mediated ubiquitin ligation, was identiﬁed. UBXN1
contains a ubiquitin-associated (UBA) motif in its N-terminus that
binds K6-linked polyubiquitin chains conjugated to BRCA1 by
autoubiquitination while the C-terminus of UBXN1 binds the
BRCA1/BARD1 heterodimer in a ubiquitin-independent fashion
[119]. Physiological relevance of the inhibition by UBXN1 remains
to be determined.
4.5. Protein degradation
Unlike some E3 ubiquitin ligases, such as MDM2, that deter-
mine their fate by autoubiquitination and self-inﬂicted degrada-
tion as a negative feed back mechanism, the autoubiquitination
of BRCA1 does not cause degradation [120]. Because the stability
of BRCA1 and BARD1 are interdependent while they acquire the
E3 ligase activity and are autoubiquitinated, the ubiquitination
may stabilize both proteins [16,19,100]. On another front, BRCA1
is unstable protein when BARD1 expression is inhibited. BRCA1
possesses a degron domain in its C-terminal ﬂanking region of
the RING ﬁnger that leads BRCA1 to proteasome-mediated degra-
dation [121]. Importantly a HECT type E3 ligase that interacts with
the degron domain of BRCA1 and ubiquitinates and degrades
BARD1-uncoupled BRCA1 was recently discovered [122]: that
was HERC2, a protein essential for RNF8-mediated HR process [11].
In physiological condition steady-state level of BRCA1 protein is
elevated throughout the mitosis. The turnover of BRCA1 and pro-
teasome-sensitive ubiquitin conjugates of BRCA1 are up-regulated
during G1 and S phases, and BARD1 inhibits the modiﬁcation [123].
HERC2 interacts with BRCA1 mainly during S-phase and interest-
ingly, the binding partner for BRCA1 was switched from HERC2
to BARD1 as cells enter mitosis accompanied by an increase in
the BRCA1 steady state level [122]. In addition BARD1 protect
BRCA1 from HERC2-mediated ubiquitination (Fig. 1). Interestingly
BRCA1 destabilization attributed to BARD1 depletion by siRNA
causes G2 checkpoint failure and additional HERC depletion re-
stores the checkpoint accompanied by BRCA1 stabilization [122].
This may suggest that HERC2 regulates checkpoint recovery or cell
cycle control by targeting BRCA1 for degradation. In response to IR
treatment HERC2 is recruited to DSBs and plays critical role in HR
as described above. In this complex BRCA1 is likely protected from
HERC2 by co-existing BARD1 and is capable of supporting Claspin-
mediated DNA replication checkpoint or G2 checkpoint activation
[124]. Upon completion of DNA repair phosphorylation of Claspin
by Plk1 triggers its SCFbTrCP-mediated degradation: a central mech-
anism for the recovery from the checkpoint to cell cycle [125].
What triggers BARD1 dissociation from BRCA1 or how BARD1 is
inhibited in physiological condition is remained to be determined.
In this regard, it is intriguing that BARD1, but not BRCA1, is a sub-
strate for anaphase promoting complex APC/C for ubiquitination
and degradation [126].5. Conclusions
Impairment of many factors involved in HR each contributes to
susceptibility to breast and ovarian cancer. They also have a critical
impact for chemo or radiosensitivity. As BRCA1 and BRCA2 contrib-
ute to HR at different impact, the phenotypes caused by deﬁciency
of these genes are different. Whereas most of BRCA1 deleterious
mutations cause basal-like breast cancer, the phenotype of BRCA2
mutations is Luminal A breast cancer. Likewise, as BRCA1 total
deletion and BRCA1 lacking E3 ligase activity may differently affect
HR competence, the phenotype and chemosensitivity attributed to
these defects would also be distinctive. Mutations that eliminate
2842 T. Ohta et al. / FEBS Letters 585 (2011) 2836–2844the E3 ligase activity of BRCA1 and multiple factors that affect the
activity may determine the chemosensitivity to certain agents in
such phenotypes. Coordination of basic and clinical research fur-
ther activates the development of this ﬁeld.
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